TLPH TALPHERA, INC. Insider Trading

CEO Angotti buys 213.3K TLPH shares at $0.59; stock down 45.2% from 52-week high, his prior TLPH buys lost 1.9%–31.0% in 90d.

Angotti Vincent J., Chief Executive Officer of TALPHERA, INC., purchased 213,310 shares at $0.59 on 2026-03-13, increasing his holdings by 36.3% from 587,395 to 800,705 shares. The company is unprofitable with net income of $-4,436,000 in the latest period and quarterly revenue of $1,000.00, while the stock trades at $0.80, down 45.2% from its 52-week high and down 14.8% over the past 30 days. His prior trades at TLPH show a consistent pattern of deterioration: five prior buys at this ticker produced 90-day returns of -1.9%, -23.0%, -14.8%, -20.5%, and -31.0%, with zero of the four measurable prior buys achieving positive 90-day outcomes. His cross-ticker track record across all open-market history shows 10 prior buys with an average 90-day return of -11.8% and a 90-day win rate of 11.11%. The confluence of a deeply distressed company, continued price deterioration, and a pattern of poorly-timed accumulation at this ticker warrants investor attention to whether this reflects unusual operational insight or represents continued pursuit of a thesis that has consistently underperformed.

CEO O bought 35,000 shares of TLPH at $0.81; stock down -46.6% from 52-week high; cluster buy by 3+ insiders in 14 days

Dasu Badri N, Chief Engineering Officer, purchased 35,000 shares (35.0K shares) at $0.81 on 2026-02-12, increasing his holdings by 90.0% from 38,884 to 73,884 shares. This purchase is noteworthy because it coincides with a pattern of insider buying: 3 other insiders also bought within the past 14 days. The transaction occurred while TALPHERA is deeply unprofitable—the company reported quarterly revenue of $1,000.00 ($1.0K) against a net loss of $-4,436,000.00 ($-4.4M), with annual revenue growth of -100.0% and negative full-year net income. The stock has declined -46.6% from its 52-week high and is trading at $0.78, down -22.0% in the past 30 days. The cluster buy pattern during significant financial distress and sharply declining price warrants detailed scrutiny into insider motivation and company fundamentals.

CMO Aslam Shakil buys 35,000 shares at $0.81; stock down -46.6% from 52-week high, cluster buy pattern ongoing.

Aslam Shakil, Chief Medical Officer, purchased 35,000 shares at $0.81 on 2026-02-12, increasing his holdings by 72.6% to 83.2K shares. The stock has declined significantly, trading at $0.78 (current price) and down -46.6% from its 52-week high of $1.46, with a 30-day decline of -22.0%. His prior two purchases at TLPH both resulted in 90-day losses (-13.2% and -5.1% respectively), and across all prior trades the cross-ticker track record shows 0% win rate at the 90-day mark with average 90d returns of -11.1%. The company faces severe headwinds: annual revenue has contracted -100.0%, most recent quarterly revenue is $1.0K, net income is negative at $-4.4M, and the company was unprofitable over its most recent full fiscal year. A cluster pattern is present with 3 other insiders also purchasing within the past 14 days; however, the insider's historical timing pattern and the company's deteriorating fundamentals provide limited basis for reading this as a meaningful confidence signal.

TLPH CEO buys 105,364 shares at $0.81; stock down -46.6% from 52-wk high; prior 5 buys at this ticker all negative at 90d.

Vincent J. Angotti, CEO of Talphera, purchased 105,364 shares at $0.81 on 2026-02-12, raising his holdings to 577,395 shares (+22.3% increase). However, the stock is now trading at $0.78, down -46.6% from its 52-week high of $1.46 and down -22.0% in just 30 days. Critically, his prior 5 buys at TLPH all posted negative 90-day returns (ranging from -8.7% to -31.0%), with a 0% win rate at the 90-day mark on this ticker. The company's fundamentals are deeply troubled: latest quarterly revenue was $1,000.00 with net income of $-4,436,000.00, annual revenue growth of -100.0%, and the company was unprofitable over its most recent full fiscal year. A cluster of 3 other insiders also bought within the past 14 days. The cumulative pattern—repeated purchases during sustained declines, deteriorating fundamentals, and prior purchasing decisions that consistently underperformed—suggests either a fundamental misreading of the business or a lack of discretion in the buying decisions.

CFO Asadorian buys 45.0K shares of TLPH at $0.81; stock down -46.6% from 52-week high amid -100.0% revenue collapse and $-4.4M loss

CFO Raffi Asadorian purchased 45,000 shares for $36,553.50, more than doubling his holdings from 43,323 to 88,323 shares. This purchase arrives as Talphera faces severe operational deterioration: annual revenue declined -100.0% in the latest period to $1,000.00, the company posted a net loss of $-4,436,000.00, and the stock has collapsed -46.6% from its 52-week high of $1.46 and -22.0% over the past 30 days. The clustering pattern—3 other insiders also bought within the past 14 days—adds weight to this transaction. The trade's significance lies in this concentration of insider buying during acute financial distress and steep price deterioration.

CEO Angotti bought 213,310 TLPH shares at $0.59 (+81.6% to holdings); stock at $0.57, down 53.3% from 52-wk high; 0 of 5 prior TLPH buys well-timed at 90d.

CEO Vincent J. Angotti purchased 213,310 shares of TALPHERA for $124,999.66 at $0.59 per share, increasing his holdings by 81.6% to 474,769 shares. The purchase occurs amid deteriorating financial fundamentals: the company reported zero revenue in its latest quarter and a $-3,353,000 net loss, with annual revenue declining 100.0% year-over-year and a market cap of only $9,746,056.65. Angotti's track record at this ticker shows poor timing: all 5 prior buys at TLPH generated negative 90-day returns, with outcomes ranging from -5.3% to -31.0%, and none were well-timed at the 90-day mark. The current stock price of $0.57 is 53.3% below the 52-week high and down 8.1% over 90 days, suggesting the recent purchase adds to a series of acquisitions into a declining position.

CMO Aslam Shakil buys 5,695 shares at $0.98–$1.07 amid 62.6% decline from 52-week high, $-3.4M net loss.

Aslam Shakil, Chief Medical Officer at TALPHERA, INC., executed 2 purchases totaling 5,695 shares for $6,038.10 at a blended average price of $1.06 on 2024-06-13 and 2024-06-14. This represents a 17.8% increase to his holdings from 32,000 shares to 37,695 shares. The purchase prices of $0.98 and $1.07 stand in stark contrast to the current price of $0.55, a -62.6% decline from the 52-week high of $1.47. The company faces significant headwinds: revenue of $0.00 in the latest quarter, annual revenue growth of -63.2%, and a full-year net loss of $-3,353,000. The timing of this purchase—following a 23.6% 30-day and 23.9% 90-day decline—occurs while the company remains unprofitable and shows revenue deterioration. An insider purchase at elevated prices relative to current valuation, within a distressed operating backdrop, warrants monitoring for whether this reflects conviction about turnaround potential or other factors.

CEO Angotti buys 5,000 TLPH shares at $0.64; stock down -53.1% from 52-week high, company posted $-3.4M net income, annual revenue down -63.2%.

Angotti Vincent J., Chief Executive Officer, purchased 5,000 shares of TALPHERA, INC. at $0.64 on 2024-12-05, increasing holdings to 208,066 shares. The purchase comes as the stock trades $0.69, down -53.1% from its 52-week high and -24.3% over the past 30 days. Fundamentally, the company reported zero revenue in the latest quarter, annual revenue decline of -63.2%, and a net loss of $-3.4M over its most recent full fiscal year. Examining Angotti's prior transaction history at this ticker reveals none of his four prior buys at TLPH achieved positive returns at the 90-day mark, and his cross-ticker track record across 7 prior buys shows an average 90-day return of -7.9% with a 16.67% win rate. The timing and execution context warrant scrutiny given the severe deterioration in both stock price and operational performance.

CEO Angotti buys 5,000 shares at $0.73; stock down 49.0% from 52-week high, 4 prior buys at TLPH all underwater at 90 days.

Angotti Vincent J., Chief Executive Officer of TALPHERA, purchased 5,000 shares at $0.73 on 2024-11-27, increasing his holdings to 203,066 shares. The stock currently trades at $0.75, down 49.0% from its 52-week high and down 25.0% over the 90-day period. The company reported revenue of $0.00 in its latest quarter with net income of -$3,353,000.00, reflecting severe operational distress and a 63.2% decline in annual revenue growth. Critically, his prior trade timing at this ticker has been uniformly poor: four previous buys in 2024 (June 12, 13, 14 and August 30) all showed negative 90-day returns ranging from -4.8% to -31.0%, with 0 of 4 prior buys well-timed at the 90-day mark. The cumulative pattern of continued insider buying into deteriorating fundamentals, compounded by a consistent history of sub-optimal purchase timing at this same ticker, suggests either compulsion to support the stock price amid operational decline or absence of disciplined timing acumen.

CEO Vincent J. Angotti bought 7,260 shares of TLPH at $1.05 (now trading at $1.00, -32.0% from 52-week high)

CEO Vincent J. Angotti purchased 7,260 shares at $1.05 on 2024-08-30, increasing his holdings by 3.8% to 198,066 shares. This is his fourth open-market buy of TLPH in three months (following purchases on 2024-06-12, 2024-06-13, and 2024-06-14), yet all three prior buys at this ticker showed negative 30-day returns (-13.6%, -4.2%, -4.4%). The stock has declined from his prior purchase prices and sits -32.0% below the 52-week high, though it has recovered +11.1% in the past 30 days. Notably, TLPH faces material headwinds: revenue is $0.00 in the latest quarter, the company posted net income of -$3,827,000.00, and annual revenue declined -63.2% year-over-year. The pattern of repeated accumulation despite poor near-term outcomes and deteriorating fundamentals merits investor scrutiny of whether these purchases reflect confidence in a turnaround or simply ongoing insider activity in an increasingly distressed position.